SCHEMBL2179897

SCHEMBL2179897

N#Cc1ccc([C](c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.59
CA2 P00918 3/20 0.50
MAOB P27338 3/20 0.50
CA1 P00915 2/20 0.50
ALDH1A1 P00352 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
MAOA P21397 2/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
CA12 O43570 1/20 0.48
CA3 P07451 1/20 0.48
CA6 P23280 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 1/20 0.47
PKM P14618 1/20 0.47
ATM Q13315 1/20 0.47
GSK3B P49841 2/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4078022 0.90 CA2 (0.58) TSHRCA2MAOBCA1ALDH1A1
SCHEMBL2178959 0.90 MAOB (0.50) TSHRCA2MAOBCA1ALDH1A1
SCHEMBL21783604 0.86 TSHR (0.59) TSHRCA2MAOBCA1ALDH1A1
SCHEMBL21783558 0.86 TSHR (0.59) TSHRCA2MAOBCA1ALDH1A1
SCHEMBL21783611 0.86 TSHR (0.59) TSHRCA2MAOBCA1ALDH1A1
SCHEMBL23456757 0.86 TSHR (0.59) TSHRCA2MAOBCA1ALDH1A1
SCHEMBL7069395 0.82 TSHR (0.61) TSHRCA2CA1ALDH1A1L3MBTL1
SCHEMBL4357019 0.82 TSHR (0.54) TSHRCA2MAOBCA1ALDH1A1
SCHEMBL10606109 0.82 TSHR (0.54) TSHRCA2MAOBCA1ALDH1A1
SCHEMBL6413833 0.82 CES2 (0.65) TSHRCA2CA1ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130172529-A1 METHOD FOR SYNTHESIZING THYMOSINS BCN PEPTIDES S.A. (ES) 2013-07-04 US disclosed
EP-2019118-B1 METHOD FOR SYNTHESIZING THYMOSINS BCN PEPTIDES SA (ES) 2012-11-07 EP disclosed
US-20110166071-A1 METHOD FOR SYNTHESIZING THYMOSINS BCN PEPTIDES S.A. (ES) 2011-07-07 US disclosed
US-20100075924-A1 DUTPASE INHIBITORS MEDIVIR AB (SE) 2010-03-25 US disclosed
US-7601702-B2 Dutpase Inhibitors MEDIVIR AB (SE) 2009-10-13 US disclosed
EP-2019118-A1 METHOD FOR SYNTHESIZING THYMOSINS BCN Peptides, S.A. (ES) 2009-01-28 EP disclosed
US-20080300216-A1 Dutpase Inhibitors MEDIVIR AB (SE) 2008-12-04 US disclosed
WO-2007132037-A1 METHOD FOR SYNTHESIZING THYMOSINS BCN PEPTIDES, S.A. (ES) 2007-11-22 WO disclosed
WO-2003046582-A2 CANCER PROGNOSIS USING THYMOSIN β10 (Tβ10) NATIONAL CENTER FOR SCIENTIFIC RESEARCH 'DEMOKRITOS' (GR) 2003-06-05 WO disclosed
EP-0609058-B1 Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses SANKYO CO (JP) 1998-12-09 EP disclosed
US-5827855-A ANTICHOLESTEROL AGENTS TREATING CARDIOVASCULAR DISORDERS; ENZYME INHIBITORS SANKYO COMPANY, LIMITED (JP) 1998-10-27 US disclosed
US-5792840-A SUBSTITUTED GLUCOPYRANOSYL PHOSPHATES SANKYO COMPANY, LIMITED (JP) 1998-08-11 US disclosed
EP-0605230-B1 Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses SANKYO CO (JP) 1997-08-27 EP disclosed
EP-0437016-B1 Lipid A analogues having immunoactivating and anti-tumour activity SANKYO CO (JP) 1996-05-01 EP disclosed
US-5491167-A INHIBITORS OF CHOLESTEROL BIOSYNTHESIS SANKYO COMPANY, LIMITED (JP) 1996-02-13 US disclosed
US-5451688-A Inhibit biosynthesis of cholesterol SANKYO COMPANY, LIMITED (JP) 1995-09-19 US disclosed
EP-0609058-A2 Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses SANKYO COMPANY LIMITED (JP) 1994-08-03 EP disclosed
EP-0437016-A2 Lipid A analogues having immunoactivating and anti-tumour activity Sankyo Company Limited (JP) 1991-07-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166071-A1 METHOD FOR SYNTHESIZING THYMOSINS PTMS, PTMA, VIP TSHR 152/4885CA2 3762/4885MAOB 3975/4885
US-20080300216-A1 Dutpase Inhibitors DUT, DHODH, POLR2H TSHR 2353/4885CA2 3008/4885MAOB 540/4885
US-20130172529-A1 METHOD FOR SYNTHESIZING THYMOSINS PTMS, PTMA, VIP TSHR 152/4885CA2 3762/4885MAOB 3975/4885
US-20100075924-A1 DUTPASE INHIBITORS DUT, DHODH, CCNO TSHR 2414/4885CA2 3019/4885MAOB 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.